Scientific Poster Session III - Original Research

Original Research
  Monday, November 13, 2023
  01:00 PM–02:30 PM

Abstract

Introduction: Long-term outcomes assessing the incidence of chronic lung allograft dysfunction (CLAD) and acute cellular rejection (ACR) who receive basiliximab induction therapy vs. no induction therapy in patients receiving lung transplantation (LTx) are poorly understood.

Research Question or Hypothesis: This study compared the incidence of CLAD, ACR, and mortality between patients who received basiliximab for induction and those who received no induction for LTx.

Study Design: This was a single-center retrospective chart review of 195 adult LTx recipients comparing those who received basiliximab for induction vs. those who received no induction between 1/2013-12/2019.

Methods: Patients were excluded if they received multi-organ transplantation or had insufficient pulmonary function test data available in the electronic health record for analysis. The primary outcome was the incidence of CLAD at 3-years post-transplant. Secondary outcomes include short- and long-term ACR rates at = and > 1-year post-transplant respectively, as well as mortality rates at 1 and 3-years post-transplant. Level of significance (alpha) was set at 0.05.

Results: In this study, 42.6% (n=83) of included LTx recipients received basiliximab for induction while 57.4% (n=112) received no induction therapy. Incidence of CLAD at 3-years post-transplant in patients who received basiliximab vs. no induction was 24.1% (n=20) and 21.4% (n=24) respectively (p=0.157). Grade A1 or greater ACR at = 1 year and at > 1 year in the basiliximab vs. no induction groups were 11.3% (n=22) and 19.5% (n=38) (p=0.220) and 7.2% (n=14) and 12.8% (n=25) (p=0.241) respectively. 3-year post-transplant mortality rates were 10.8% (n=9) vs. 16.1% (n=18) in the basiliximab and no induction groups respectively (p=0.157).

Conclusion: As compared to patients who did not receive induction therapy, use of basiliximab for induction in LTx recipients was not significantly associated with greater 3-year incidences of CLAD, while long-term ACR and mortality rates may be lower in patients who received basiliximab vs. those who received no induction.

Presenting Author

Prasannaraddi Alavandi PharmD
Stanford Health Care

Authors

Roy Lee PharmD, BCPS
Stanford Health Care

Erik Henricksen PharmD, BCPS
Stanford Health Care

Laveena Chhatwani MD
Stanford Health Care

Allison Vu PharmD
Stanford Health Care